Core Viewpoint - The company, Yaoshi Bang, has initiated a share buyback plan of up to HKD 100 million, signaling strong market confidence and a commitment to enhancing shareholder value [1][3][8]. Group 1: Share Buyback and Management Actions - The company announced a share buyback plan to utilize up to HKD 100 million by October 31, 2025, and has already repurchased 3.707 million shares since the announcement, with a total expenditure exceeding HKD 27.74 million [1][3]. - Executive director Chen Fei increased his stake by purchasing 500,000 shares in April and an additional 100,000 shares on May 15 [2]. Group 2: Financial Performance and Growth - For the year 2024, the company reported a revenue of CNY 17.904 billion, a year-on-year increase of 5.5%, significantly outperforming the industry average [4]. - The company achieved a net profit of CNY 30.01 million, marking its first full-year profit, with adjusted net profit reaching CNY 157 million, a 20.1% increase year-on-year [4][5]. - Operating cash flow remained positive at CNY 656 million, reflecting a 45% year-on-year growth, indicating strong financial health [4][6]. Group 3: Operational Efficiency and Market Position - The company has a healthy debt structure with total liabilities of CNY 4.226 billion, primarily consisting of accounts payable [6]. - The company maintains a unique cash cycle with inventory turnover days of approximately 30 days and accounts receivable turnover days close to zero, allowing for efficient cash management [6]. - As of December 2024, the company had over 827,000 registered buyers, covering 98.9% of counties and 91.2% of townships in China, with a monthly active buyer count of 433,000 and a payment rate of 92.7% [4]. Group 4: Future Growth Potential - The company is positioned for significant growth with a projected compound annual growth rate of 145% in net profit from 2024 to 2027, driven by the successful implementation of high-margin proprietary brand initiatives [8][9]. - The ongoing optimization of grassroots medical resource allocation in China is expected to further enhance the company's growth prospects, as it stands to benefit from increased demand in the pharmaceutical procurement sector [9].
盈利拐点确立、估值反击战打响，市场热烈回应药师帮（09885）亿元回购